A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study.
Joachim LinssenAnthony ErmensMarvin BerrevoetsMichela SeghezziGiulia PrevitaliSimone Van Der Sar-Van Der BruggeHenk RusscherAnnelies VerbonJudith GillisJürgen RiedlEva de JonghJarob SakerMarion MünsterImke Ca MunnixAnthonius DofferhofVolkher ScharnhorstHeidi AmmerlaanKathleen DeiterenStephan Jl BakkerLucas Joost Van PeltYvette Kluiters-de HinghMathie Pg LeersAndré J A M van der VenPublished in: eLife (2020)
COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration, and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.
Keyphrases
- sars cov
- coronavirus disease
- healthcare
- end stage renal disease
- clinical trial
- chronic kidney disease
- emergency department
- ejection fraction
- peritoneal dialysis
- mental health
- cell therapy
- respiratory syndrome coronavirus
- study protocol
- adverse drug
- peripheral blood
- mechanical ventilation
- acute respiratory distress syndrome
- drug induced